Molecular therapy targets being investigated include several receptor tyrosine kinases (e.g., PDGFR, EGFR), downstream cascades (e.g., PI3K/Akt/mTOR), brachyury (a transcription factor unique to chordoma), and the FGF/MEK/ERK pathway. The gene discussed is AKT1; the disease is chordoma.